# A Study of Tor Kinase Inhibitor in Advanced Tumors

> **NCT00731263** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 64 (actual)

## Conditions studied

- Solid Tumors

## Interventions

- **DRUG:** AZD8055

## Key facts

- **NCT ID:** NCT00731263
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-07
- **Primary completion:** 2010-11
- **Final completion:** 2010-11
- **Target enrollment:** 64 (ACTUAL)
- **Last updated:** 2012-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00731263

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00731263, "A Study of Tor Kinase Inhibitor in Advanced Tumors". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00731263. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*